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This editorial refers to ‘Difference in percentage of
ventricular pacing between two algorithms for minimizing
ventricular pacing: results of the IDEAL RVP (Identify
the Best Algorithm for Reducing Unnecessary Right
Ventricular Pacing) study’ by Y. Murakami et al.,o n
page 96.
Pacing from the right ventricular apex has been the clinical stan-
dard for decades but has recently come into question with a
growing trend towards reducing ventricular pacing as much as
possible. The earliest devices provided asynchronous ventricular
pacing in patients whose indication for pacing was asystolic com-
plete heart block. RV apical pacing was literally the difference
between life and death. Over the decades, as technology has
advanced allowing the medical community to more closely
model normal cardiac physiology, we have seen the progressive
introduction of demand function, single-chamber atrial pacing,
dual-chamber pacing, dual-chamber rate-modulated pacing, and in
the past decade, cardiac resynchronization pacing. During this evol-
ution, it has been noted that pacing from the right ventricular apex,
even in the presence of high-grade AV block, may contribute to
ventricular dysfunction associated with the disordered ventricular
activation sequence associated with the paced left bundle branch
block pattern.
‘Pacemaker syndrome’ or the adverse haemodynamics associ-
ated with a technically normal pacing system was rarely recognized
in the late 1960s when complete heart block was the indication for
implantation. Its recognition blossomed in the 1980s with the
introduction of dual-chamber pacing systems and an increase in
the relative indications for permanent pacing including individuals
who only needed pacing on an intermittent basis or whose
primary indication for pacing was sinus node dysfunction. Pace-
maker syndrome was usually associated with a loss of appropriate
atrial transport (atrioventricular synchrony) and was able to be
corrected by upgrading a patient with a single-chamber VVI
pacing system to a DDD pacing system.
1–3 The standard location
for the ventricular lead during the ﬁrst four decades of cardiac
pacing was the RV apex. The ﬁrst generation of DDD pacemakers
had limited AV delay programmability such that there was either
full ventricular pacing or consistent ventricular fusion. On the
basis of multiple studies, DDD pacing was clinically superior to
VVI pacing, particularly when pacing was required for a large per-
centage of the time. The progressive symptoms of heart failure
occurring over the ensuing decades were attributed to the
progression of the patient’s underlying disease.
It was not until the onset of cardiac resynchronization therapy
that the clinical community began to appreciate the potentially
adverse consequences of a disordered ventricular activation
sequence, be it spontaneous as with an endogenous left bundle
branch block or iatrogenic with RV apical ventricular pacing.
On the basis of pacing studies demonstrating DDD pacing was
superior to VVI pacing, the device manufacturers introduced dual-
chamber ICDs (VVED). The medical profession rapidly embraced
dual-chamber ICDs, reasoning that both haemodynamics and
supraventricular tachycardia discrimination with the addition of
the atrial lead would be improved. No studies had been done. In
the late 1990s, the DAVID trial was initiated in an effort to deter-
mine whether there was a beneﬁt of DDD pacing over VVI pacing
in a population of patients requiring ICD therapy.
4 One of the
entry criteria to participate in the DAVID trial was the requirement
that the patient did not require pacing. The patients were then
assigned to one of two groups, one with the pacing component
of the ICD programmed to VVI at 40 bpm providing back-up
heart rate support should delivery of high-voltage therapy be fol-
lowed by a period of asystole. The second group was programmed
to the DDD mode at a base rate of 70 bpm. Programming the AV
delay was left to the discretion of the investigator at each partici-
pating medical centre. A majority of physicians left the paced and
sensed AV delays at the shipped values of 170/150 ms, respectively.
The primary endpoint for the DAVID study was a composite end-
point of death or worsening or new heart failure resulting in hos-
pitalization. The data were monitored on a periodic basis by the
*Corresponding author. Tel: þ1 818 493 2900, Fax: þ1 818 362 2242, Email: plevine@sjm.com
The opinions expressed in this article are not necessarily those of the Editors of Europace or of the European Society of Cardiology.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
Europace (2010) 12,1 1 – 1 4
doi:10.1093/europace/eup384Data Safety and Monitoring Board, with the investigators at each
centre blinded to the results. The study was stopped prematurely
in 2002 owing to an increase in the primary endpoint in the DDD
group compared with the VVI group. The initial assumption was
that the adverse outcome in the DDD group was directly due
to the abnormal ventricular activation sequence although the
study was not designed to evaluate that speciﬁc question. In the
light of the DAVID results, investigators involved in other studies
such as the Mode Selection Trial (MOST), MADIT II, and
Midas
5–8 retrospectively examined their data and arrived at a
similar conclusion. Those patients with a signiﬁcant percentage of
ventricular pacing had a higher incidence of heart failure, hospital-
izations, and atrial ﬁbrillation, leading to an effort to develop algor-
ithms that would minimize ventricular pacing. Except for MIDAS,
all the other studies involved patients who either did not require
pacing at all or required primarily atrial pacing.
There were two other hypotheses for the adverse impact
associated with an increase in ventricular pacing in the above
studies. One was that the adverse effects seen in the DDD
group was due to too high a paced rate essentially increasing meta-
bolic demand with worsening ischaemia and ventricular dysfunc-
tion. The DAVID II trial was initiated to compare VVI pacing at
40 with AAI pacing at 70 in a second group of patients who
required ICD but not pacemaker therapy. This study was not ter-
minated prematurely, and when the data were examined, there
was virtually no difference between the two groups, effectively
excluding the higher base rate pacing as a culprit.
The second hypothesis involved the AV delay. In a patient with
intact AV nodal conduction, the only way to achieve ventricular
pacing is to programme too short an AV delay. Sharma et al.
9
examined the bradycardia diagnostics integral to the St Jude
Medical ICDs that were implanted in the DAVID study. They
found a group of patients in whom the physician had programmed
a long AV delay to facilitate intrinsic AV nodal conduction. This
resulted in three distinct groups of patients. If the percent ventri-
cular pacing exceeded 40%, there was a high incidence of adverse
haemodynamic effects including worsening heart failure. The
lowest percentage of ventricular pacing was associated with VVI
pacing (,4%); however, unlike the data that were originally pre-
sented in the DAVID study, this very low incidence of ventricular
pacing was not associated with the best results. Rather, the lowest
incidence of adverse events was associated with the long AV delay
group. Patients who require an ICD commonly have signiﬁcant
ventricular dysfunction. They are likely to have intermittent ﬁrst
and even higher grades of AV block, although documenting this
is difﬁcult because there were no special diagnostics that would
allow these episodes to be captured and counted. Although VVI
pacing protects the patients from asystole, it does not maintain
AV synchrony, nor support the patient at a higher rate for intermit-
tent potentially adverse events that could contribute to some of
the endpoints. The long AV delay group had an incidence of ven-
tricular pacing of 11%, and it was this subgroup that had the
lowest incidence of heart failure and other complications. The
results of this analysis were presented at the annual scientiﬁc ses-
sions of the Heart Rhythm Society in 2005 and published the same
year, but it was not generally appreciated by the clinical
community.
During the same time period, Boston Scientiﬁc sponsored the
INTRINSIC RV trial.
10 It was virtually identical to DAVID except
in one very important area. Programming the AV delay was speciﬁ-
cally deﬁned in the study protocol. Entry criteria included a
requirement for high-voltage therapy and intact AV nodal conduc-
tion such that the patient did not require pacing support. There
was a VVI group and a DDD group. The DDD group was
further divided into a ﬁxed AV delay of 200 ms (which was
longer than the usual AV delay programmed in the DAVID trial)
or an AV delay of 200 ms plus Boston Scientiﬁc’s AV Search Hys-
teresis
w (AVSH) algorithm, which could increase the AV delay to a
maximum of 300 ms and would maintain the longer AV delay as
long as AV nodal conduction was intact and shorter than
300 ms. The study results were presented in 2007 by Olshansky
et al.
10 Similar to DAVID, this study demonstrated that the
group with .40% ventricular pacing had the highest adverse
event rate. Also, similar to the DAVID trial, the group programmed
to the VVI mode had the lowest incidence of ventricular pacing,
but this group did not have the lowest incidence of endpoint
events. The lowest incidence of endpoint events occurred in the
DDD group in which the AVSH algorithm had been enabled
with an 11–19% incidence of ventricular pacing.
Even preceding the results of the DAVID study, manufacturers
had been looking at various algorithms designed to minimize ven-
tricular pacing in the patients who required atrial pacing with only
back-up ventricular support should high-grade AV block develop.
Although some groups were strong advocates of dedicated single-
chamber atrial pacing, many physicians were concerned that either
the progression of AV conduction system disease or the addition
of drugs that could further compromise AV nodal conduction
might lead to problems in the usual pacemaker patient who is
elderly. Further, even though AV nodal conduction at rest was
intact, if the AV conduction system was stressed by higher rates,
the patient could develop AAIR pacemaker syndrome,
11,12 where
the atrial paced, ventricular sensed interval, rather than shortening
as occurs with normal physiology,
13,14 would progressively
lengthen, causing the atrium to be depolarized and contract
against a closed mitral and tricuspid valve associated with the sys-
tolic contraction caused by the previous atrial paced complex con-
ducted with a ﬁrst-degree AV block. It was increasingly recognized
that marked ﬁrst-degree AV block could be very symptomatic at
low activity levels and that a permanent dual-chamber pacing
system was indicated with impressive clinical improvement
despite the occurrence of virtually 100% ventricular pacing.
15,16
Acknowledging that unnecessary ventricular pacing could have
adverse haemodynamic consequences with worsening cardiac
function, precipitation of clinically symptomatic heart failure, and
predisposing to atrial ﬁbrillation, manufacturers pursued two differ-
ent routes in attempting to minimize unnecessary ventricular
pacing. The ﬁrst included the introduction of a variety of paced
and sensed AV delay hysteresis algorithms. With these algorithms,
the clinician sets the AV delays that would be most appropriate for
the patient if AV block were to develop. As long as atrioventricular
nodal conduction was intact, the programmed AV delay would be
extended by a second interval (a delta), and as long as a sensed
R-wave occurred within this extended paced or sensed AV
delay, the system would function as if it were a single-chamber
Editorial 12atrial pacemaker. With the occurrence of ventricular pacing at the
end of the extended AV delay anywhere from 1 to a programmable
number of cycles depending on the speciﬁc algorithm, the AV delay
extension would be suspended and the AV delay would be shor-
tened to the original programmed value.
17,18 After a period of
time or a predetermined number of cycles, the pulse generator
would perform a search by extending the AV delay. If the AV
block had resolved and a sensed R-wave was detected within the
extended AV delay, the AV delay would remain at that longer inter-
val until such time as ventricular pacing again occurred, causing the
AV delay to shorten to its programmed value. Currently, all man-
ufacturers have algorithms that function along these lines and all
have unique terms to describe their speciﬁc algorithm. As a
group, I will simply call these AV Hysteresis algorithms.




basically says ‘no’ to any and all ventricular pacing unless high-grade
AV block is present. Profound ﬁrst-degree AV block will persist as
long as the sensed R-wave occurs before the next paced or sensed
atrial event is detected. If intermittent low-grade second-degree
AV block less than a stable 2:1 block occurs but is not sustained,
the algorithm will allow for potentially long pauses (up to two
paced or sensed atrial cycles) on a repeated but not consecutive
basis. Even complete heart block might not disengage the MVP
algorithm if there is a sufﬁciently rapid ventricular escape
rhythm. If and when the algorithm is disengaged, similar to the
AV Hysteresis algorithms, there is a search function occurring
periodically where the system withholds a ventricular output and
looks to see whether intact AV nodal conduction has returned,
at which time it will resume the MVP algorithm. In the electrically
unstable patient, the pauses in the ventricular rate may predispose
to pause-dependent tachyarrhythmias such as Torsade-de-Pointes.
A related but not identical algorithm was introduced by Sorin-ELA
called AAIsafeR
w.
21 It differs from Medtronic’s MVP algorithm in
that it incorporates a programmable maximum AV delay up to
450 ms to prevent the potential marked pauses that have been
reported with the MVP algorithm. It also incorporates a variety
of event counter diagnostics including a tabulation of the number
of times the device exited the AAIsafeR algorithm, the reasons
for exiting, and examples captured on electrogram snapshots.
Murakami et al.
22 reported the results of the Medtronic-
sponsored IDEAL RVP study. This study compared Medtronic’s
AV Hysteresis algorithm (Search AVþ) with their MVP algorithm.
As both algorithms were available in the Medtronic Adapta
w dual-
chamber pacemaker, this was a within-patient, randomized,
crossover-designed study where each mode was engaged for
1 month. The speciﬁc end result was the percentage of ventricular
pacing. The net results were predictable. There were single-digit
percentages of ventricular pacing in the MVP mode, whereas
there was a signiﬁcantly higher percentage of ventricular pacing
in the Search AVþ mode. Although this is statistically signiﬁcant,
the question that should be asked and was not able to be assessed
was whether this was clinically signiﬁcant, and more importantly,
was the lesser degree of ventricular pacing in association with
the MVP algorithm always safe given only 1 month of follow-up
for each arm of the study. In addition, there are no internal diag-
nostics included in the Medtronic Adapta pacemaker to count
the number of times the system exited MVP to restore DDD
pacing or the speciﬁc arrhythmias that induced the exit from
MVP. Although ventricular pacing is currently considered to be
less than optimal, this is ventricular pacing with an abnormal ven-
tricular activation sequence. One cannot determine from the
event counter diagnostics whether the ventricular paced beat
was a fusion with a near-normal ventricular activation sequence
or a fully paced wide QRS complex. One hundred and forty
patients were enrolled in the study but 13 dropped out, leaving
127 patients for analysis. The maximal paced and sensed AV
delay with the Search AVþ algorithm enabled was 500 and
450 ms, respectively, although the maximal allowed AV delay was
not a requirement of the study. The per cent atrial pacing was
similar in both pacing modes. The study did not exclude patients
with AV block, and in Table 4, patients with various degrees of
AV block had a signiﬁcantly lower percentage of ventricular
pacing than the Search AVþ group. To look just at the per cent
ventricular pacing, 57.5% of the patients had ,10% ventricular
pacing when MVP was enabled, whereas this was 38.6% in patients
programmed with Search AVþ (P , 0.0001). Although this is
highly signiﬁcant on a statistical basis, the question if this is either
safe or appropriate must be asked. With respect to patients with
normal AV conduction, if based on the literature, 40% ventricular
pacing is the cut-off for adverse consequences of ventricular
pacing, 100% of the patients when programmed to the MVP had
,10% ventricular, whereas this was 79.6% when the Search
AVþ algorithm had been enabled. One hundred per cent of the
MVP mode had ,40% ventricular pacing, whereas this was
98.1% when programmed to the Search AVþ algorithm.
The analysis of the Intrinsic RV study and the re-analysis of the
bradycardia diagnostics from the DAVID study suggest that main-
taining both rate and AV synchrony are important to patients
with impaired ventricular function. Most ICD patients, whether
this be for primary prevention or secondary prevention, have
impaired ventricular function. With respect to patients who
require pacing support for standard indications, Chiladakis et al.
23
demonstrated that the long-term outcome is based on underlying
ventricular function independent of ventricular pacing or intact AV
nodal conduction.
The follow-up period of only 1 month in each pacing mode in
the IDEAL RVP trial precludes an assessment of the long-term
consequences of each of the pacing modalities. In addition,
although the data are relatively strong with respect to maintaining
AV synchrony and a normal ventricular activation when both the
PR interval and the QRS duration are normal, there are no data
available with respect to the patient who has an abnormal ventri-
cular activation sequence.
24 There are data with respect to patients
with signiﬁcant ﬁrst-degree AV block with a normal ventricular
activation sequence will often do better with dual-chamber
pacing programmed to an appropriate AV delay despite the
forced abnormal ventricular activation sequence. There is limited
but enticing evidence that pacing from the RV outﬂow tract may
be able to provide the needed ventricular pacing with a near-
normal ventricular activation sequence. This would allow the clin-
ician to programme an optimal AV delay for a given patient while
still maintaining near-normal ventricular function in the setting of
ventricular pacing. A study involving patients with AV block who
Editorial 13will require ventricular pacing comparing RV apical pacing RV
outﬂow tract pacing with biventricular pacing needs to be done
with a follow-up of 5 years or longer.
As Murakami et al. point out, the IDEAL RVP study was not
designed to assess the clinical value of one mode over the other.
The follow-up interval was too short and the lack of diagnostics
internal to the pacemaker limited their ability to determine how
the system functioned between ofﬁce visits and whether or not
this was always optimal for each subject. Disease is rarely static,
and the requirements at the time of implantation will change
with the progression of disease as well as the addition of pharma-
cological therapy and various co-morbidities. It is strongly rec-
ommended that as we go forward, for those patients who
require ventricular pacing, even in the presence of ‘just’ ﬁrst-
degree AV block, one should select a physiologically appropriate
AV delay rather than the blanket desire to eliminate all ventricular
pacing. Combining this with an alternate site of ventricular pacing
might further improve the long-term outcomes but this has yet
to be proved.
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